Literature DB >> 23937822

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.

Tatsuhiko Saito1, Kei Ohnuma, Hiroshi Suzuki, Nam H Dang, Ryou Hatano, Hiroki Ninomiya, Chikao Morimoto.   

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1α level.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CD26; DPP-4; DPP-4 inhibitors; Polyarthropathy; SDF-1α

Mesh：

Substances：

Year:  2013        PMID： 23937822     DOI： 10.1016/j.diabres.2013.07.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  10 in total

1.  Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Authors:  Jong-Mi Seong; Jeong Yee; Hye Sun Gwak
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

Review 2.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

Review 3.  Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.

Authors:  Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Maurizio Sessa; Daniela Cimmaruta; Francesco Rossi; Annalisa Capuano
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

4.  Role of the neutrophil chemorepellent soluble dipeptidyl peptidase IV in decreasing inflammation in a murine model of arthritis.

Authors:  Sarah E Herlihy; Monica L Brown; Darrell Pilling; Brad R Weeks; Linda K Myers; Richard H Gomer
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

Review 5.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

6.  DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY.

Authors:  Z A Sayiner; B Okyar; B Kısacık; E Akarsu; M Özkaya; M Araz
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

7.  Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.

Authors:  Pragya Rai; Nilanjana Dwibedi; Mazhgan Rowneki; Drew A Helmer; Usha Sambamoorthi
Journal:  Am Health Drug Benefits       Date:  2019-09

8.  Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.

Authors:  B M Bonora; A Avogaro; G P Fadini
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

9.  Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network.

Authors:  Qian Gao; Wenjun Zhang; Tingting Li; Guojun Yang; Wei Zhu; Naijun Chen; Huawei Jin
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.